"Camptothecin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Descriptor ID |
D002166
|
MeSH Number(s) |
D03.132.151
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Camptothecin".
Below are MeSH descriptors whose meaning is more specific than "Camptothecin".
This graph shows the total number of publications written about "Camptothecin" by people in this website by year, and whether "Camptothecin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 2 | 1 | 3 |
1996 | 7 | 1 | 8 |
1997 | 2 | 0 | 2 |
1998 | 4 | 2 | 6 |
1999 | 3 | 0 | 3 |
2000 | 6 | 1 | 7 |
2001 | 4 | 2 | 6 |
2002 | 12 | 2 | 14 |
2003 | 17 | 1 | 18 |
2004 | 13 | 2 | 15 |
2005 | 6 | 6 | 12 |
2006 | 9 | 11 | 20 |
2007 | 4 | 5 | 9 |
2008 | 6 | 9 | 15 |
2009 | 5 | 10 | 15 |
2010 | 4 | 9 | 13 |
2011 | 2 | 8 | 10 |
2012 | 4 | 5 | 9 |
2013 | 7 | 7 | 14 |
2014 | 1 | 8 | 9 |
2015 | 4 | 2 | 6 |
2016 | 4 | 4 | 8 |
2017 | 2 | 8 | 10 |
2018 | 3 | 0 | 3 |
2019 | 2 | 0 | 2 |
2020 | 3 | 2 | 5 |
2021 | 1 | 1 | 2 |
2022 | 1 | 3 | 4 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Camptothecin" by people in Profiles.
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
-
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin Cancer Res. 2023 01 04; 29(1):174-182.
-
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022 12 02; 12(12):2754-2762.
-
Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea. Food Chem Toxicol. 2022 Aug; 166:113246.
-
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 07 07; 387(1):9-20.
-
Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation. Chem Biol Interact. 2022 Jun 01; 360:109946.
-
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? Oncology. 2022; 100(3):182-187.
-
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 06; 22(6):779-789.
-
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. Oncologist. 2021 02; 26(2):e261-e269.
-
Reply to T.J.A. Dekker. J Clin Oncol. 2020 10 01; 38(28):3351-3352.